Arcus Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
February 21, 2024 at 09:05 pm
Share
Arcus Biosciences, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported revenue was USD 31 million compared to USD 34 million a year ago. Net loss was USD 81 million compared to USD 67 million a year ago. Basic loss per share from continuing operations was USD 1.08 compared to USD 0.93 a year ago.
For the full year, revenue was USD 117 million compared to USD 112 million a year ago. Net loss was USD 307 million compared to USD 267 million a year ago. Basic loss per share from continuing operations was USD 4.15 compared to USD 3.71 a year ago.
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
ARCUS BIOSCIENCES, INC. 
